SCHEMBL5620539

SCHEMBL5620539

COC(=O)c1cc(N2CCCC2=O)cc(S(C)(=O)=O)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.47
MEN1 O00255 2/20 0.47
ALDH1A1 P00352 5/20 0.46
HPGD P15428 2/20 0.46
CYP1A2 P05177 1/20 0.46
CYP3A4 P08684 1/20 0.46
CYP2D6 P10635 1/20 0.46
CYP2C9 P11712 1/20 0.46
CYP2C19 P33261 1/20 0.46
PKM P14618 3/20 0.45
LMNA P02545 2/20 0.45
NPSR1 Q6W5P4 2/20 0.45
RXFP1 Q9HBX9 2/20 0.45
KDM4E B2RXH2 1/20 0.45
TP53 P04637 1/20 0.43
MAPK1 P28482 1/20 0.43
SMN1; SMN2 Q16637 2/20 0.42
MAPT P10636 1/20 0.42
NPC1 O15118 3/20 0.42
RAB9A P51151 3/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5219104 0.88 ALDH1A1 (0.56) KMT2AMEN1ALDH1A1HPGDCYP1A2
SCHEMBL475775 0.86 MEN1 (0.56) KMT2AMEN1ALDH1A1HPGDCYP1A2
SCHEMBL5219444 0.86 MEN1 (0.56) KMT2AMEN1ALDH1A1HPGDCYP1A2
SCHEMBL5221769 0.82 POLB (0.48) KMT2AMEN1ALDH1A1HPGDCYP1A2
SCHEMBL5221306 0.82 ALDH1A1 (0.58) KMT2AMEN1ALDH1A1HPGDCYP1A2
SCHEMBL5219191 0.81 CA12 (0.53) KMT2AMEN1ALDH1A1HPGDCYP1A2
SCHEMBL2533613 0.81 MEN1 (0.51) KMT2AMEN1ALDH1A1HPGDCYP1A2
SCHEMBL5241791 0.81 MEN1 (0.51) KMT2AMEN1ALDH1A1HPGDCYP1A2
SCHEMBL5217876 0.80 MEN1 (0.50) KMT2AMEN1ALDH1A1HPGDCYP1A2
SCHEMBL5218738 0.80 KMT2A (0.53) KMT2AMEN1ALDH1A1HPGDCYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7160905-B2 Hydroxyethylene compounds with Asp2 inhibitory activity SMITHKLINE BEECHAM P.L.C. (GB) 2007-01-09 US disclosed
US-20050038028-A1 Hydroxyethylene compounds with asp2 inhibitory activity SMITHKLINE BEECHAM P.L.C. (GB) 2005-02-17 US disclosed
EP-1448516-A1 HYDROXYETHYLENE COMPOUNDS WITH ASP2 INHIBITORY ACTIVITY SMITHKLINE BEECHAM PLC (GB) 2004-08-25 EP disclosed
WO-2003045903-A1 HYDROXYETHYLENE COMPOUNDS WITH ASP2 INHIBITORY ACTIVITY SMITHKLINE BEECHAM P.L.C. (GB) 2003-06-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050038028-A1 Hydroxyethylene compounds with asp2 inhibitory activity BACE2, BACE1, PSEN2 KMT2A 2372/4885MEN1 574/4885ALDH1A1 1269/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.